Griffin Securities issues $6.00 price target for Cormedix

 Email Article  

Tweet  

  

  

 delicious  

  

  

Griffin Securities are initiating coverage on CorMedix Inc. (NYSE AMEX: CRMD) with a BUY rating and a 12 - month price target of $6.00 for CRMD shares.

Griffin Securities is a research-driven investment banking firm providing corporate finance, merger & acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. The firm is a member of the Financial Industry Regulatory Authority (FINRA) (www.finra.org) and the Securities Investor Protection Corporation (SIPC) (www.sipc.org). Griffin Securities is headquartered in New York City and has no other domestic or international affiliates or subsidiaries. They focus on small to medium sized public and private companies provides the highest level of service to clients. In addition to the private placement of equity and debt securities with institutional investors and high net worth individuals, our investment banking services include financial advisory services, such as mergers and acquisitions, joint ventures, and capital market transactions.

CorMedix Inc. (AMEX:CRMD) is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney (cardiorenal) disease.

Cardiorenal disease includes a broad range of inter-related cardiovascular, kidney and metabolic problems which share the common trait of underlying oxidative stress and blood vessel malfunction (endothelial dysfunction).

Griffin Securities Report on Cormedix.